Glaucoma
Conditions
Interventions
Sponsors
Hospital, University of the Ryukyus
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Written informed consent: Patients capable of providing written consent by themselves after full explanation of the study details using a written information to patients. (2) Patients with glaucoma poorly responding to the treatment of prostaglandins, beta-blocker and CAI for more than 2 month (regardless of PG analogues, beta-blocker and CAI) (3) Patients aged 20 years or older who are capable of providing consent. (4) Males and females.
Exclusion criteria
Exclusion criteria: (1) Patients who have undergone an operation (including laser operation) within 3 months before the study. (2) Patients who have difficulty in measuring intraocular pressure using an applanation tonometer. (3) Patients who have difficulty or are unable to undergo fundoscopy (corneal opacity, severe cataract, etc.). (4) Patients expected to require operation for an eye disease during the study period. (5) Patients with serious renal impairment (nephrotic syndrome, acute renal failure, chronic renal failure, etc.) (6) Patients with hepatic function disorder. (7) Patients with bronchial asthma or its history. (8) Patients with bronchospasm or serious chronic obstructive pulmonary disease. (9) Patients with cardiac failure, sinus bradycardia, atrioventricular block (second and third degrees), or cardiogenic shock. (10) Patients with right cardiac failure due to pulmonary hypertension. (11) Patients with congestive cardiac failure. (12) Patients with diabetic ketoacidosis and/or metabolic acidosis. (13) Patients with poorly controlled diabetes mellitus. (14) Patients with a anamnestic history of hypersensitivity to any ingredients of the investigational product. (15)Patients who has received administration of the adrenocortical steroid agent (Skin local administration other than an eye circumference part is good). (16) During a pregnant woman, the nursing or a patient with possibility becoming pregnant. (17) Patients whom it was judged a doctor not to be suitable as an object of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of intraocular pressure (trough & peak) before and after instillation | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Japan
Contacts
Public ContactYoshikuni Arakaki
Hospital, University of the Ryukyus Department of Ophthalmology
Outcome results
None listed